Dr. Tolaney on Neoadjuvant HER2-Directed Therapy

Sara M. Tolaney, MD, MPH
Published: Tuesday, Aug 01, 2017



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy.

Since 2013, pertuzumab (Perjeta)-based chemotherapy has primarily been used for patients in the preoperative setting based on the results of the NeoSphere and TRYPHAENA trials, explains Tolaney. However, now there are data in the adjuvant setting looking at the long-term benefits of pertuzumab with the APHINITY trial. The data suggest that the disease-free survival benefit appears to be small with a 1.7% difference.

The approach in the neoadjuvant setting is going to change, according to Tolaney. Pertuzumab-based chemotherapy was being used for the majority of tumors that were more than 2 centimeters, but that may no longer be necessary since not all patients are going to gain long-term benefits from pertuzumab.
 


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy.

Since 2013, pertuzumab (Perjeta)-based chemotherapy has primarily been used for patients in the preoperative setting based on the results of the NeoSphere and TRYPHAENA trials, explains Tolaney. However, now there are data in the adjuvant setting looking at the long-term benefits of pertuzumab with the APHINITY trial. The data suggest that the disease-free survival benefit appears to be small with a 1.7% difference.

The approach in the neoadjuvant setting is going to change, according to Tolaney. Pertuzumab-based chemotherapy was being used for the majority of tumors that were more than 2 centimeters, but that may no longer be necessary since not all patients are going to gain long-term benefits from pertuzumab.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x